ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

The introduction of tyrosine kinase inhibitors (TKI) for the treatment of metastatic non-small cell lung cancer (NSCLC) harbouring sensitizing epidermal growth factor receptor (EGFR) gene mutations revolutionized the diagnostic and treatment algorithm of this subset of patients almost two decades ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega-Franco, Ana, Rafee, Shereen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098707/
https://www.ncbi.nlm.nih.gov/pubmed/35294773
http://dx.doi.org/10.1007/s40487-022-00190-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098707/
https://www.ncbi.nlm.nih.gov/pubmed/35294773
http://dx.doi.org/10.1007/s40487-022-00190-8

Ejemplares similares